Actionable news
0
All posts from Actionable news
Actionable news in VRX: VALEANT PHARMACEUTICALS INTERNATIONAL,

Citron's Andrew Left: Yes, I'm long Valeant, but...

Citron Research Executive Editor Andrew Left said Tuesday he does not think Valeant Pharmaceutical shares will trade above $60 anytime soon, despite taking a long position in the stock.

"You still might say the stock is uninvestable," he told CNBC's "Fast Money: Halftime," a day after unveiling his new position on the stock.

"I bought some stock [in Valeant]; I also protected myself and bought some out-of-the-money puts. I also saw...


More